12.07.2015 Views

PDF, Patent Landscape Report on Atazanavir - WIPO

PDF, Patent Landscape Report on Atazanavir - WIPO

PDF, Patent Landscape Report on Atazanavir - WIPO

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

CLINICAL NAMINGClinical names are far more usable than chemical names from the searcher’s point of view.They are distinctive and crucially, they are the same in any language. These names are thebest resource for compiling a collecti<strong>on</strong> of patents that could be called “Clinical Collecti<strong>on</strong>”because they relate to the drug after it has begun to be tested clinically.Figure 3. Time Sequence of Drug-NamingMANUFACTURER NAMINGThe inventors of <strong>Atazanavir</strong> were chemists at Novartis (then Ciba-Geigy). Novartis calledthe compounds that they were testing CGP-73547, CGP-75355 and CGP-75136. Novartismade an agreement with Bristol-Myers Squibb for further development, manufacturing, andclinical trials work. Bristol-Myers Squibb called the compositi<strong>on</strong> being tested BMS-232632,and this name was very comm<strong>on</strong>ly used in later publicati<strong>on</strong>s.GENERIC NAMINGThe name <strong>Atazanavir</strong> is a n<strong>on</strong>-proprietary generic name that will stay with the drug nomatter which company makes or sells its bioequivalents in the future. <strong>Atazanavir</strong> follows anaming protocol (USAN – United States Adopted Name) that was selected for applicati<strong>on</strong> todrugs in the same class (HIV-Protease Inhibitors). Usually a US manufacturer submits acandidate for its adopted name when the US FDA has approved an investigati<strong>on</strong>al newdrug applicati<strong>on</strong> (IND) and there are clinical trials starting. There is interacti<strong>on</strong> between theUSAN Council 5 and the Internati<strong>on</strong>al N<strong>on</strong>proprietary Name (INN) Program of World HealthOrganizati<strong>on</strong> (WHO) to coordinate these names globally.BRAND NAMINGLast, when the drug is tested and approved, it is known by a proprietary (brand) nameregistered for trademark protecti<strong>on</strong> by the company that owns/sells it. During the time whena compositi<strong>on</strong> is protected by a patent, <strong>on</strong>ly the originating company will have a brand5A group co-sp<strong>on</strong>sored by the American Medical Associati<strong>on</strong>, the United States Pharmacopeial C<strong>on</strong>venti<strong>on</strong>(USP), and the American Pharmacists Associati<strong>on</strong> http://www.ama-assn.org/ama/pub/physicianresources/medical-science/united-states-adopted-names-council.page10

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!